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Severe obesity (BMI ≥ 40 kg/m2) is associated with multiple defects in skeletal muscle which contribute to insulin resistance and a
reduction in fatty acid oxidation (FAO) in this tissue. These metabolic derangements are retained in human skeletal muscle cells
raised in culture. Together, these findings are indicative of a dysfunctional global metabolic program with severe obesity which is of
an epigenetic or genetic origin. Weight loss via gastric bypass surgery can “turn oﬀ” and/or correct components of this metabolic
program as insulin sensitivity is restored; however, the impairment in FAO in skeletal muscle remains evident. Physical activity can
improve FAO and insulin action, indicating that this patient population is not exercise resistant and that exercise oﬀers a pathway
to circumvent the abnormal program. Findings presented in this review will hopefully increase the understanding of and aid in
preventing and/or treating the severely obese condition.
1. Introduction
Our research group has been studying the intricacies of
skeletal musclemetabolism in severely obese patients (BMI≥
40 kg/m2) for more than 25 years. These studies were initially
possible due to collaborating surgeons providing abdominal
muscle (rectus abdominus) biopsies taken during gastric
bypass surgery which were then utilized in a muscle strip
preparation to study carbohydrate and lipid metabolism.
These in vitro incubation studies were complimented with
experiments using needle biopsies of a leg muscle (vastus
lateralis). Because of the substantial amount of informa-
tion that we have accumulated, it seemed appropriate to
describe and summarize the metabolic profile of the skeletal
muscle of these patients and the eﬀects of gastric bypass
surgery.
We recently began to examine the characteristics of
skeletal muscle cell cultures derived from biopsies obtained
from lean and severely obese donors. To our surprise, the
metabolic profile of myotubes raised in culture from severely
obese individuals displayed the same phenotype as the intact
muscle from which they were taken. This finding suggests
that the metabolic profile of skeletal muscle observed in
severely obese individuals is not solely due to the in vivo
environment of the patient, but rather to a constitutive
“obesity metabolic program” that is either genetically or
epigenetically determined. We believe this represents a
paradigm shift in our thinking about metabolic regulation
in obesity. This review will focus on our studies that support
the concept of a metabolic program in the skeletal muscle
of severely obese individuals. Alternative hypotheses on
the relationships between lipid oxidation, insulin action,
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and obesity can be examined in other papers on this topic
[1–6].
2. The Metabolic Profile of the Skeletal
Muscle of Severely Obese Individuals
2.1. Insulin Action. In the early 1980s we developed a human
skeletal muscle strip preparation that was suitable for in vitro
incubation experiments to study metabolism [7]. During
elective abdominal surgery a biopsy of the rectus abdominus
was clamped, excised, and “teased” into 12–20 muscle fiber
strips. This preparation was exceptionally versatile as almost
any radiolabeled substrate could be utilized in the incubation
media to study metabolism and the eﬀects of any hormone
could be tested by incubation in its presence and absence.
The first published paper using this preparation [7]
reported that glucose transport was stimulated approxi-
mately 2.5-fold by insulin in tissue from lean controls, but
there was little or no stimulation of glucose transport in
muscle from severely obese patients either with or without
type 2 diabetes. We subsequently found that glucose trans-
port in the muscle of severely obese patients, both diabetic
and nondiabetic, was also resistant to the action of insulin-
like growth factor-1 (IGF-1) [8]. Cumulative data from years
of similar experiments indicated that for individuals with
a BMI ≤ 20 kg/m2 glucose transport was stimulated by
approximately 3-4 fold, but there was a progressive decline
in insulin responsiveness to a BMI of about 30 kg/m2, after
which there was virtually no insulin-induced stimulation [9].
Glucose transport was not the only parameter that
demonstrated a reduced response to insulin. Insulin stimu-
lation of glycogen formation, glucose oxidation, and nonoxi-
dized glycolysis were all depressed in muscle of severely obese
patients [10]. Interestingly, lactate release was not stimulated
by insulin but basal (absence of insulin) lactate release was
much higher in obese than nonobese controls suggesting a
preferential utilization of carbohydrate rather than lipid as a
fuel source.
To investigate the mechanism(s) of insulin resistance
with severe obesity we addressed the question of whether
a stimulus other than insulin could increase glucose trans-
port in insulin-resistant muscle. In obese Zucker rats we
demonstrated that muscle contraction stimulated glucose
transport normally, even though there was severe insulin
resistance [11]. We were not able to make the human muscle
fiber strips contract but we did observe that hypoxia and
vanadate, two stimuli that are believed to function through
pathways also activated with muscle contraction, stimulated
glucose transport normally in muscle strips from severely
obese, insulin-resistant individuals [12, 13]. From these data
we concluded that the mechanism for the translocation
of the insulin-sensitive glucose transporter (GLUT4) was
functional and the defect must be upstream and within
the signaling pathway leading to insulin-mediated glucose
transport. In support of this hypothesis, insulin stimulation
of insulin receptor and IRS-1 tyrosine phosphorylation
as well as activation of PI-3 kinase and Akt were all
substantially reduced with severe obesity [14, 15]. The
activities of protein-tyrosine phosphatases (PTPase 1B and
LAR) [16], which would be predicted to impair insulin signal
transduction, were also increased in muscle fiber strips of
severely obese patients compared to nonobese controls.
Partially purified insulin receptors from muscle of
severely obese subjects displayed tyrosine kinase activity that
was lower than in nonobese controls [17]. We believe this
is a result of hyperphosphorylation of serine residues on
the insulin receptor, as phosphatase treatment substantially
increased tyrosine kinase activity in receptors from the
muscle of severely obese subjects [18, 19]. IRS-1 frommuscle
of severely obese patients was also hyper-phosphorylated,
especially on serine 312 [20]. These changes in serine phos-
phorylation were accompanied by increased kinase activities
of PKC and IKK [19, 20]. The involvement of PKC was also
implicated by the finding that insulin resistance could be
induced by a phorbol ester and insulin sensitivity restored
in obese muscle with a PKC inhibitor [21]. Based on these
findings our hypothesis is that several kinases are activated
in the muscle of severely obese individuals with subsequent
serine phosphorylation of the insulin receptor and IRS-1.
These modifications depress insulin signal transduction and
stimulation of glucose transport, glycogen synthesis, glucose
oxidation, and nonoxidized glycolysis.
2.2. Fat Metabolism. Skeletal muscle plays a critical role in
controlling whole-body fatty acid oxidation (FAO) due to
its mass and metabolic characteristics. At rest FAO is the
predominant activity of skeletal muscle [22]; thus any factor
which would elicit a decrement in FAO in skeletal muscle
could be anticipated to lead to the preferential partitioning
of ingested lipid towards ectopic fat accumulation. As an
example of FAO influencing body composition, subsequent
weight gain was associated with a lower whole-body FAO as
determined with indirect calorimetry [23]. A reduction in
the activity of an enzyme in skeletal muscle involved with
lipid metabolism (β-HAD) was associated with a reduced
ability for whole-body FAO, indicating the potentially impor-
tant role of the characteristics of this tissue in controlling
body mass [24].
To test the hypothesis that a reduction in FAO in skeletal
muscle is evident with obesity, we incubated muscle strips
from the rectus abdominus with 14C-labeled palmitate and
measured the production of labeled CO2 as the index of
FAO [25]. To our surprise, FAO did not diﬀer in the
muscle of lean (BMI, 23.8 ± 0.6 kg/m2), and obese (30.2 ±
0.8 kg/m2) individuals but exhibited a significant reduction
in the muscle of severely obese (BMI, 53.8 ± 0.4 kg/m2)
subjects (−60% compared to lean controls) [25]. In a follow-
up study, FAO was determined in needle biopsies from
the vastus lateralis using a muscle homogenate preparation
to measure labeled CO2; FAO was reduced by ∼60%
compared to lean controls in individuals approximating
severe obesity (BMI, 38.3 ± 3.1 kg/m2) [26]. In a subsequent
experiment we confirmed this reduction in FAO and found
that the proportion of lipid that remained in the acid-
soluble fraction (acid soluble metabolites, ASM), which is
an index of incomplete oxidation, was elevated with severe
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obesity [27]. Together, these findings provide convincing
evidence indicating a reduction in FAO in the skeletal muscle
of severely obese individuals, as FAO was reduced in two
separate muscle groups from diﬀerent anatomical areas with
markedly diﬀering function and recruitment patterns (i.e.,
postural versus locomotion). This observation is critical as
skeletal muscle is a heterogeneous tissue that can vary widely
in respect to fiber composition, metabolic characteristics,
and neural innervation.
Carnitine palmityoltransferase (CPT-1) regulates the
transport of long-chain fatty acids across the mitochondrial
membranes and is thus a key regulatory step for the control
of FAO. The incubation of needle biopsy samples (vastus
lateralis) with several species of fatty acids was utilized to
determine if metabolic steps at either the level of CPT-1 or
downstreamwere impaired with severe obesity [26]. The oxi-
dation of palmitoyl carnitine, which enters the mitochondria
independently of CPT-1, was depressed indicating that post-
CPT-1 mechanisms in either β-oxidation and/or the TCA
Cycle contribute to the reduction in FAO with severe obesity.
In support of this observation citrate synthase, a TCA cycle
enzyme and general indicator of mitochondrial content, was
depressed in both the vastus lateralis and rectus abdominus
of severely obese subjects [26]. However, CPT-1 activity was
also reduced with severe obesity indicating a defect at this
level in addition to downstream alterations [26]. Proteome
analyses revealed increases in glycolytic enzymes (adenylate
kinase, GAPDH, aldolase A, and creatine kinase activity)
which was hypothesized to reflect a metabolic drift towards
glycolytic energy production with the decrease in FAO in
skeletal muscle with severe obesity [28]. This observation
is supported by the increased generation of lactate under
resting conditions that we have observed in the muscle
strips [10]. These findings provide evidence for a metabolic
program in the skeletal muscle of severely obese individuals
where multiple steps are aﬀected in a manner reflecting a
decrement in FAO.
The observation of a reduction in FAO with severe
obesity could also be attributed to a reduction in substrate
availability, that is reduced fatty acid transport into the
muscle of severely obese patients. However, long-chain fatty
acid transport rates into giant sarcolemmal vesicles from the
muscle of obese individuals were upregulated by ∼4-fold
compared to lean controls; this elevation in fatty acid trans-
port with obesity was associated with an increased presence
of the fatty acid transporter FAT/CD36 at the sarcolemma
and an increase in intramuscular triacylglycerol content [29].
Our group has also reported increased intramuscular lipid
content with severe obesity which was associated with a
preferential partitioning of lipid towards storage rather than
oxidation [30]. Such a scenario is metabolically disadvan-
tageous as intramuscular lipid accumulation can be linked
with insulin resistance [31]. In addition, intramuscular lipid
comprises a relatively small reservoir for whole-body lipid
storage as only 1–3% of total muscle area is occupied
by lipid droplets [32, 33]. The reduction in FAO could
potentially result in an overall partitioning of lipid away
from anabolic/catabolic processes in skeletal muscle and
towards deposition in adipose tissue which may explain the
observation of weight gain in individuals with a depressed
whole-body FAO [23].
We have also reported that the skeletal muscle of
severely obese individuals, both diabetic and nondiabetic, is
comprised of a lower relative percentage of type I muscle
fibers (myosin ATPase staining) compared to lean controls
[34, 35]. Type I, sometimes known as red, muscle fibers are
characterized as being insulin-sensitive and geared towards
oxidative metabolism compared to type II (white) muscle
fibers; in support, insulin action in rectus abdominus
strips was positively related to the relative percentage of
type I muscle fibers [34]. This predominance of type II
fibers with severe obesity is again suggestive of a general
phenotype in the muscle of these patients which favors a low
capacity for lipid oxidation and insulin resistance. However,
we have observed that muscle fiber type is not altered
in severely obese subjects in response to an intervention
which improves insulin action such as gastric bypass/weight
loss [20, 36, 37]. Such data indicates that contractile (i.e.
fiber type) and metabolic characteristics may not always be
congruent.
3. Metabolism in Cultured Myotubes from
Severely Obese Individuals Is Similar to
that in Intact Muscle
Following procedures originally described by Henry et al.
[38] we developed methods for culturing cells from human
muscle biopsy samples. Briefly, nascent satellite cells are
released by trypsin treatment from the muscle and trans-
ferred to collagen-coated flasks which provide a matrix
for subsequent attachment and proliferation into myoblasts
[39]. Proliferation of the myoblasts continues in a serum-
rich media in an incubated environment until confluence
is obtained, which typically requires 4–6 weeks. Although
metabolic studies can be performed in myoblasts, we have
elected to examine myotubes as they more closely resemble
mature skeletal muscle and express many of the genes that
are characteristic of skeletal muscle in vivo [40]. In our
experiments the metabolic characteristics of the myotubes
are typically studied after 5–8 days of diﬀerentiation.
Human skeletal muscle cells (HSkMC) raised in cul-
ture oﬀer a unique system for studying metabolism in
relation to health and disease. The influence of potential
acute adaptive factors such as neural input, hormonal
concentrations, and physical activity level on metabolic
characteristics in HSkMC are essentially removed due to the
length and nature of the proliferation and diﬀerentiation
phases [38, 41, 42]. Thus, it is believed that characteristics
exhibited in HSkMC primarily reflect genetic or epige-
netic traits. In addition, the experimental manipulations
permitted in cell culture far exceed those possible in vivo.
Our findings of remarkably similar metabolic character-
istics between HSkMC and skeletal muscle examined in
vivo or in vitro from severely obese donors oﬀers an
experimental system enabling a more in-depth study of
potential mechanisms explaining the obesity-related pheno-
type.
4 Journal of Obesity
3.1. Insulin Action. Henry et al. [38] were the first to
report that HSkMC from patients with type 2 diabetes
retained the insulin resistance exhibited in intact muscle.
We extended this finding to obesity by demonstrating that
insulin stimulation of IRS-1 tyrosine phosphorylation and
Akt phosphorylation was significantly blunted in HSkMC
from severely obese patients [43, 44]. In addition, serine 312
of IRS-1 was significantly more phosphorylated in myotubes
from severely obese patients than lean controls. Figure 1
shows the comparison of our published data using the
muscle strip preparation and HSkMC from lean and severely
obese subjects. The degree of stimulation of IRS-1 tyrosine by
insulin was approximately 60% in the severely obese muscle
compared to lean controls and was essentially reproduced
in HSkMC. The degree of blunting of Akt activation and
serine 312 IRS-1 phosphorylation were even greater in
HSkMC than observed in intact muscle (Figure 1). These
data suggest that there are constitutive changes in insulin
signaling in the skeletal muscle of severely obese patients
that are retained in human skeletal muscle cells raised in
culture.
3.2. Fat Metabolism. As already presented in this review,
FAO in the skeletal muscle of severely obese individuals is
consistently reduced, which likely contributes to the prefer-
ential partitioning of lipid towards storage. As presented in
Figure 1, the relative magnitude of the reduction in com-
plete (labeled CO2 production) and increase in incomplete
(ASM/CO2) FAO are virtually identical in HSkMC compared
to intact muscle strips or muscle homogenates [27, 30, 43,
45]. This reduction in FAO does not appear to be due
to a reduction in fatty acid uptake as we have reported
elevated fatty acid transport into HSkMC from severely
obese individuals [43]. Indices of lipid partitioning towards
storage are also similar and may even be slightly elevated
in HSkMC [27, 30, 43, 45]. These findings indicate that the
metabolic signature evident in the skeletal muscle of severely
obese individuals in relation to lipidmetabolism is essentially
retained in HSkMC (Figure 1) and perhaps of a genetic or
epigenetic origin.
Gene array and subsequent PCR analyses indicated a 2-
fold elevation in stearoyl-CoA desaturase-1 (SCD-1) mRNA
in skeletal muscle biopsies from severely obese individuals;
this diﬀerence was retained in HSkMC [30]. SCD-1 is a
lipogenic enzyme which preferentially directs palmitoyl-CoA
(C16:0) and stearoyl-CoA (C18:0) towards the synthesis of
triacylglycerol, phospholipid, and cholesterol esters within
the cell. In knockout mouse models, the absence of SCD-1
protected the animals against both diet-induced and genetic
forms of obesity [46]; based on these finding, the increased
SCD-1 evident with severe obesity would be anticipated
to favor the development of obesity-related conditions.
This causal relationship was substantiated when SCD-1
was overexpressed in HSkMC from lean subjects and a
reduction in FAO along with increased lipid storage was
observed; these alterations resulted in a marked shift of lipid
partitioning towards storage and away from oxidation [30].
The fact that both FAO and lipid storages were altered with
overexpression suggests that SCD-1may impart amultitiered
level of control by altering the intracellular content of lipid
ligands which can function as signaling molecules for gene
transcription.
A reduction in mitochondrial content may also con-
tribute to the decrease in FAO evident with severe obesity.
In HSkMC, Consitt et al. [45] reported a reduction in
FAO, increase in incomplete FAO, increased incorporation
into TAG and diacylglycerol (DAG) pools, and an overall
preferential partitioning of lipid towards storage rather
than oxidation in severely obese subjects. Mitochondrial
content, as determined by mitochondrial DNA copy number
(mtDNA) and COXIV protein content, was also significantly
reduced in the cultures derived from the severely obese
donors; however, after correction for mitochondrial content
(i.e., FAO/mtDNA; FAO/COXIV) FAOwas equivalent in lean
and obese subjects. These findings suggest that the mito-
chondria of severely obese individuals function normally in
respect to lipid oxidation and that the overall reduction in
FAO can be attributed to a lower mitochondrial content
[45]. Overexpression of PGC-1α, a transcriptional coacti-
vator that stimulates mitochondrial biogenesis, increased
mitochondrial content and FAO in HSkMC from severely
obese individuals [45]. However, FAO remained depressed
compared to lean controls, which suggests that the severely
obese state limits both mitochondrial biogenesis and oxida-
tive capacity via mechanisms that are independent of PGC-
1α abundance. Together, these data obtained in HSkMC
[30, 45] demonstrate that lipid oxidation is inherently
reduced in the skeletal muscle of severely obese individuals
due to decrements in multiple steps of lipid metabolism.
We have also observed that HSkMC from severely obese
subjects secretes myostatin, a myokine which inhibits protein
synthesis, at a high rate; the impact of this alteration on
energy metabolism is not yet, however, evident [47].
4. The Effect of Lipid Exposure on Metabolic
Programs in Severely Obese Individuals
4.1. Insulin Action. It is well established that a high-fat diet
causes insulin resistance in skeletal muscle. Because fatty
acids are potent metabolic regulators as well as substrates,
we investigated the eﬀects of incubating HSkMC from lean
and severely obese subjects in fatty acids for 12 to 48 hours.
Consistent with our hypothesis, fatty acids caused insulin
resistance in HSkMC from lean controls. Fatty acid exposure
decreased values for IRS-1 serine 312 phosphorylation as well
as insulin stimulation of IRS-1 and Akt in cells from lean
controls to values approximating those in myotubes from
severely obese subjects (Figure 2). Since cells from severely
obese subjects were already insulin resistant there was no
further eﬀect of fatty acid incubation.
Activation of AMP kinase (AMPK) is known to reverse
insulin resistance in many animal models and metformin
may increase insulin sensitivity in humans through this
mechanism. Therefore, we tested whether activation of
AMPK could reverse insulin resistance in HSkMC from
severely obese individuals. AICAR (an activator of AMPK)
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Figure 1: Comparison of insulin signal transduction and fatty acid oxidation in intact skeletal muscle and human skeletal muscle cells
raised in culture (HSkMC) from lean and severely obese donors. Data in the graphs were calculated from mean values in the cited
papers and nonobese control values used as 100%. (a) Insulin-stimulated tyrosine phosphorylation of IRS-1 (Phos-IRS-1) [14, 43, 44].
(b) Insulin-stimulated Akt phosporylation (Phos-Akt) [15, 43, 44]. (c) IRS-1 serine 312 phosphorylation (S312-IRS-1) [20, 43, 44].
(d) Complete fatty acid oxidation as determined from labeled CO2 production from 14C labeled palmitate (CO2) [25, 27, 43, 45]. (e)
Incomplete fatty acid oxidation from calculating the 14C from labeled palmitate remaining in the acid soluble metabolite fraction divided
by labeled CO2 production (ASM/CO2) [27, 43, 45]. (f) Partitioning between lipid synthesis and fatty acid oxidation (synthesis/CO2)
[25, 30, 43, 45].
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Figure 2: Comparison of insulin signal transduction and fatty acid metabolism in human cultured skeletal muscle cells (HSkMC) from
lean and severely obese individuals that were incubated in the presence or absence of free fatty acids for 16 hours. The values shown in the
graphs were calculated from mean values in published papers. The values for muscle cells from lean individuals in the absence of fatty acids
were used as 100%. (a) Insulin stimulated tyrosine phosphorylation of IRS-1 (Phos-IRS-1) [44]. (b) Insulin stimulated Akt phosporylation
(Phos-Akt) [44]. (c) IRS-1 serine 312 phosphorylation (S312-IRS-1) [44]. (d) Complete fatty acid oxidation as determined from labeled CO2
production from 14C labeled palmitate (CO2) [43, 45]. (e) Incomplete fatty acid oxidation from calculating the 14C from labeled palmitate
remaining in the acid soluble metabolite fraction divided by labeled CO2 production (ASM/CO2) [43, 45]. (f) Partitioning between lipid
synthesis and fatty acid oxidation (synthesis/CO2) [25, 30, 43, 45].
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incubation rescued insulin signal transduction in HSkMC
from severely obese subjects or cells from lean controls
treated with fatty acids [44]. These results suggest that
treatment of insulin-sensitive skeletal muscle with fatty acids
induces insulin resistance to a degree equivalent to HSkMC
from severely obese subjects. Likewise, insulin resistance
caused by either fatty acid treatment or severe obesity can
be reversed through the activation of AMPK.
4.2. Fat Metabolism. Consumption of a high fat diet is also
known to alter lipid metabolism; we therefore hypothesized
that treating muscle cells with fatty acids would aﬀect the
oxidation and storage of fatty acids. HSkMC from lean and
severely obese subjects were treated with fatty acids for 12 to
48 hours and then studied. Consistent with earlier published
results [30, 45] we again observed that FAO was initially
depressed and fatty acid storage enhanced in HSkMC from
severely obese individuals [43]. Interestingly, treatment of
HSkMC from lean subjects with fatty acids for 48 hours
elicited an elevation in incomplete FAO and increased lipid
storage to the point that the phenotype of the lean cells
approximated that seen in severely obese individuals. These
results led us to the hypothesis that there is a constitutive
metabolic program in the skeletal muscle of severely obese
patients that can be induced in cells of lean individuals by
treatment with fatty acids.
The evidence indicating a relatively global dysfunction in
lipid metabolism with severe obesity [25, 26, 43] prompted
an investigation of gene regulation in the skeletal muscle
of severely obese subjects. In lean individuals we observed
that a 5-day high-fat diet (HFD) (65% of total energy from
fat) increased the expression of genes which would enhance
FAO in skeletal muscle such as PDK4, PPARα, and PGC-1α
[48]. This finding is congruent with other data indicating
an elevation in FAO as an adaptive response in lean subjects
to additional dietary lipid [49, 50]. However, we observed
no increases in these genes with the HFD in the muscle of
severely obese subjects [48] which is in agreement with the
lack of a response to fatty acid incubation in HSkMC [43].
These findings indicate a relatively global dysregulation at
the level of gene expression which may be involved with
the impaired FAO evident in skeletal muscle with severe
obesity.
If our obesity metabolic program hypothesis is correct,
a related question is whether the program can be “turned
oﬀ” and metabolism returned to values similar to lean
individuals. Two interventions that were available for us to
test this question were weight loss induced by gastric bypass
surgery and physical activity.
5. The Metabolic Program in Skeletal Muscle
with SevereObesityCanBePartiallyReversed
by Gastric Bypass Surgery
5.1. Insulin Action. To test whether weight loss after gastric
bypass could reverse the insulin resistance of severe obesity
we studied a group of women who lost approximately 50 kg
after surgery and were weight stable for at least 3 months
(surgery/weight loss group) [20]. Despite weight loss the
subjects still had a BMI of approximately 30 kg/m2 and were
classified as obese. Data from the surgery/weight loss group
was compared to (1) severely obese women (2) weight-
and age-matched women who were never severely obese,
and (3) age-matched, but lean (BMI < 25 kg/m2) women.
As expected, a whole-body insulin sensitivity index (SI
determined from a frequently sampled intravenous glucose
tolerance test) demonstrated dramatic insulin resistance in
the severely obese compared to the other groups [20].
Interestingly, SI of the surgery/weight loss group was not
diﬀerent than the lean group and was higher than in the
weight-matched women. Comparisons of insulin-mediated
glucose transport in vitro in muscle fiber strips obtained
during surgery generally matched the diﬀerences seen in
whole body insulin action (SI) [20]. Likewise, muscle IRS-
1 serine 312 phosphorylation in the surgery/weight loss
group matched that of the lean group and was significantly
lower than that of the severely obese or the weight-matched
groups [20]. Thus, the weight loss induced by gastric bypass
not only reverses insulin resistance, but actually improves
insulin sensitivity to a degree that is superior to that seen
in weight-matched controls. This improvement in insulin
action cannot be attributed to increased physical activity
after gastric bypass which is equivalent between previously
severely obese surgery patents andweight-matched sedentary
controls [51].
Prospective studies have confirmed that gastric bypass
surgery dramatically enhances insulin action in severely
obese patients [36, 37, 52]. In these experiments, we obtain
measurements at approximately one year after surgery, as
patients are weight stable by the time [53]; data are thus
not confounded by responses evident with negative energy
balance. In terms of possible mechanisms explaining this
improvement, we observed that there was no change in the
concentration of the insulin-sensitive glucose transporter
(GLUT4) [52]. Insulin receptor concentration, however,
doubled with weight loss which may contribute to the
improvement in insulin action seen with the interven-
tion [54]. Gene array and RT-PCR analyses indicated
that growth factor receptor-bound protein 14, glycerol-3-
phosphate dehydrogenase, and myostatin were elevated with
severe obesity but significantly reduced with weight loss
[55]. Pathway analyses indicated the involvement of these
and other genes in weight-loss responsive networks which
would be expected to improve insulin signaling, decrease
triglyceride synthesis, and increase muscle mass with gas-
tric bypass/weight loss [55]. However, the predominance
of insulin-resistant, glycolytic muscle fibers evident with
severe obesity [35] was not altered with gastric bypass
surgery/weight loss [36], although a higher initial percentage
of type I fibers was associated with increased weight loss
[35]. In contrast, intramuscular TAG and long-chain fatty
acyl-CoA concentrations (palmityl, stearate, and linoleate
CoA) were dramatically reduced with gastric bypass/weight
loss [36, 37]. This reduction in intramuscular lipid content
could contribute to the improvement in insulin action seen
with gastric bypass surgery as intracellular lipids can induce
insulin resistance [44].
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5.2. Fat Metabolism. An impaired capacity for FAO has been
linked with insulin resistance through the accumulation
of lipid-related metabolites which impede insulin signal
transduction or other mechanisms [56]. Conversely, a high
capacity for FAO in skeletal muscle has been positively asso-
ciated with insulin sensitivity independent of intramuscular
lipid content [57]. An increase in FAO in skeletal muscle
with gastric bypass/weight loss could thus explain both the
improvement in insulin action and reduction in intracellular
lipid content evident at one year after the intervention [36,
37, 52]. However, our studies indicate that the depressed FAO
evident with severe obesity is not altered with gastric bypass
surgery/weight loss.
Using needle biopsies from the vastus lateralis Berggren
et al. [27] compared FAO in severely obese women after
gastric bypass surgery/weight loss to (1) lean controls and
(2) severely obese individuals. FAO was virtually equivalent
in the muscle from the gastric bypass surgery/weight loss
and severely obese groups and depressed compared to
the lean women. Incomplete lipid oxidation (ASM/CO2)
was also elevated compared to lean controls in both the
gastric bypass/weight loss and severely obese groups. With
a prospective study design, we again observed no eﬀect
of gastric bypass surgery/weight loss on complete and
incomplete FAO in the skeletal muscle of women who lost
55 kg to achieve a mean BMI of 30.5 ± 2.3 kg/m2 [27].
These findings in skeletal muscle were supported by studies
that utilized whole-body indices of FAO. Infusion of labeled
tracers (13C palmitate and 14C acetate) indicated that FAO
remained equivalent in gastric bypass surgery/weight loss
and severely obese women and depressed compared to
lean controls [58]. A comparison of fat utilization during
submaximal exercise (indirect calorimetry) also indicated
that whole-body lipid oxidation was depressed in women
who had lost weight via gastric bypass surgery compared to
weight-matched controls [51].
In summary, insulin action is improved with gastric
bypass surgery/weight loss to the extent that previously
severely obese subjects are even more insulin sensitive than
weight-matched controls. Gastric bypass surgery/weight loss
does not, however, rescue the reduction in FAO in skeletal
muscle evident with severe obesity. If an impaired FAO is
linked with weight gain [23], the inability to alter FAO with
weight loss intervention may explain why some individuals
are predisposed to severe obesity and weight regain after
dietary-induced weight loss. The mechanical limitations
imposed on energy intake by the gastric bypass procedure
may be the only practical and eﬀective intervention to insure
long-term weight loss in this patient population. The data
gathered from our work also suggests that the optimal
treatment strategy for the metabolic aberrations evident with
severe obesity would consist of weight loss coupled with an
intervention that would increase FAO in skeletal muscle.
6. The Obesity Metabolic Program Can Be
Reversed by Exercise
6.1. Insulin Action and Fat Metabolism. The eﬀects of exercise
training on skeletal muscle are well documented and include
improving insulin action and increasing FAO. It thus seems
intuitive that exercise would be eﬀective in alleviating the
insulin resistance and reduction in FAO in skeletal muscle
evident with severe obesity. However, there are reports of an
“exercise resistance” in obese/diabetic patients in terms of
eliciting mitochondrial biogenesis [59, 60] which could also
be evident in severely obese individuals as both populations
share the common traits of insulin resistance and a reduction
in FAO [56]. In relation to insulin action, we examined the
eﬀects of 7 consecutive days of exercise (60 min/day, ∼65%
VO2peak) on severely obese men [61]. This relatively acute
training prescription was utilized as body mass is not altered;
thus any changes can be primarily attributed to the eﬀects of
contractile activity alone. Exercise training reduced fasting
and two-hour insulin concentrations and also reduced the
insulin area under the curve during an oral glucose tolerance
test, indicating improved insulin action.
A similar acute training prescription (10 consecutive
days, 60min/day,∼70% VO2 Peak) was utilized to determine
the impact of physical activity on FAO [27]. Three groups
of subjects were examined: (1) lean (BMI < 25 kg/m2); (2)
obese but not severely obese and (3) previously severely obese
subjects who had lost weight through gastric bypass surgery.
Complete FAO (labeled CO2) in skeletal muscle biopsies was
initially reduced and incomplete FAO (ASM/CO2) elevated
in the gastric bypass/weight loss compared to the lean and
obese groups. Exercise training increased complete FAO by
∼2-fold in the lean and obese groups and, despite the initial
decrement, also increased FAO in the gastric bypass/weight
loss group to the degree that it did not diﬀer between the
lean, obese, and weight loss groups after the intervention.
Incomplete oxidation was also normalized after exercise
training in the skeletal muscle of the gastric bypass/weight
loss group [27]. No diﬀerences in the responses of PDK4,
CPT-1, and PGC-1αmRNA to training were evident between
the groups. These findings [27, 61] indicate that exercise
training can be used to alleviate the phenotype/metabolic
program of insulin resistance and reduced FAO evident with
severe obesity, although the cellular mechanism(s) remain to
be defined.
7. Conclusions
Severe obesity (BMI ≥ 40 kg/m2) is associated with insulin
resistance in skeletal muscle due to impairments in multiple
steps of the insulin signaling pathway. Increased intramus-
cular lipid content and a reduction in FAO, both conditions
linked with insulin resistance, are also evident in the skeletal
muscle of severely obese individuals. The deficit in FAO in
skeletal muscle with severe obesity may also help explain
a propensity towards the development of obesity/severe
obesity and weight gain in these individuals as lipid is
partitioned towards storage rather than oxidation.
The impaired insulin signal transduction and depressed
FAO from intact skeletal muscle remained apparent in
human skeletal muscle cells (HSkMCs) raised in culture
from severely obese donors. It is believed that characteristics
exhibited in HSkMC primarily reflect genetic or epigenetic
traits. These data have led us to believe that the skeletal
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muscle of severely obese individuals displays a global
metabolic program which results in insulin resistance and
impaired FAO.We believe this concept represents a paradigm
shift in our concepts about metabolic regulation in obesity.
This metabolic program can be induced with fatty
acid exposure in HSkMC. In contrast, weight loss via
gastric bypass surgery can “turn oﬀ” components of this
metabolic program as insulin sensitivity is restored or even
enhanced compared to weight-matched controls with the
intervention. However, gastric bypass/weight loss does not
rescue the decrement in FAO in skeletal muscle evident
with severe obesity. This consistent retention of a reduced
FAO may explain why severely obese individuals are prone
to weight gain and weight-regain after diet-induced weight
loss and why the mechanical limitations imposed on energy
intake by the gastric bypass procedure provides an eﬀective
intervention. Physical activity can improve FAO and insulin
action in severely obese individuals, indicating that this
patient population is not “exercise resistant”; physical activity
should thus be considered as an adjunct to weight loss
intervention. In conclusion, it is hoped that the research
summarized in this review can aid in preventing and/or
treating the severely obese condition.
Acknowledgments
This work was supported by NIH Grants RO1DK46121
(GLD) and RO1DK56112 (JAH).
References
[1] N. Turner and L. K. Heilbronn, “Is mitochondrial dysfunction
a cause of insulin resistance?” Trends in Endocrinology and
Metabolism, vol. 19, no. 9, pp. 324–330, 2008.
[2] J. F. Dumas, G. Simard, M. Flamment, P. H. Ducluzeau, and
P. Ritz, “Is skeletal muscle mitochondrial dysfunction a cause
or an indirect consequence of insulin resistance in humans?”
Diabetes and Metabolism, vol. 35, no. 3, pp. 159–167, 2009.
[3] E. Phielix and M. Mensink, “Type 2 diabetes mellitus and
skeletal muscle metabolic function,” Physiology and Behavior,
vol. 94, no. 2, pp. 252–258, 2008.
[4] J. O. Holloszy, “Skeletal muscle “mitochondrial deficiency”
does not mediate insulin resistance,” American Journal of
Clinical Nutrition, vol. 89, no. 1, pp. 463S–466S, 2009.
[5] M. A. Abdul-Ghani and R. A. DeFronzo, “Mitochondrial
dysfunction, insulin resistance, and type 2 diabetes mellitus,”
Current Diabetes Reports, vol. 8, no. 3, pp. 173–178, 2008.
[6] M. A. Abdul-Ghani, F. L. Muller, Y. Liu et al., “Deleterious
action of FA metabolites on ATP synthesis: possible link
between lipotoxicity, mitochondrial dysfunction, and insulin
resistance,” American Journal of Physiology, vol. 295, no. 3, pp.
E678–E685, 2008.
[7] G. L. Dohm, E. B. Tapscott, W. J. Pories et al., “An in vitro
human muscle preparation suitable for metabolic studies.
Decreased insulin stimulation of glucose transport in muscle
from morbidly obese and diabetic subjects,” Journal of Clinical
Investigation, vol. 82, no. 2, pp. 486–494, 1988.
[8] G. L. Dohm, C. W. Elton, M. S. Raju et al., “IGF-I-
stimulated glucose transport in human skeletal muscle and
IGF-I resistance in obesity and NIDDM,” Diabetes, vol. 39, no.
9, pp. 1028–1032, 1990.
[9] C. W. Elton, E. B. Tapscott, W. J. Pories, and G. L. Dohm,
“Eﬀect of moderate obesity on glucose transport in human
muscle,” Hormone and Metabolic Research, vol. 26, no. 4, pp.
181–183, 1994.
[10] J. E. Friedman, J. F. Caro, W. J. Pories, J. L. Azevedo, and
G. L. Dohm, “Glucose metabolism in incubated human
muscle: eﬀect of obesity and non- insulin-dependent diabetes
mellitus,” Metabolism, vol. 43, no. 8, pp. 1047–1054, 1994.
[11] P. L. Dolan, E. B. Tapscott, P. J. Dorton, and G. L. Dohm,
“Contractile activity restores insulin responsiveness in skeletal
muscle of obese Zucker rats,” Biochemical Journal, vol. 289, no.
2, pp. 423–426, 1993.
[12] J. L. Azevedo Jr., J. O. Carey, W. J. Pories, P. G. Morris, and G.
L. Dohm, “Hypoxia stimulates glucose transport in insulin-
resistant human skeletal muscle,” Diabetes, vol. 44, no. 6, pp.
695–698, 1995.
[13] J. O. Carey, J. L. Azevedo, P. G. Morris, W. J. Pories, and
G. L. Dohm, “Okadaic acid, vanadate, and phenylarsine
oxide stimulate 2-deoxyglucose transport in insulin-resistant
human skeletal muscle,” Diabetes, vol. 44, no. 6, pp. 682–688,
1995.
[14] L. J. Goodyear, F. Giorgino, L. A. Sherman, J. Carey, R. J. Smith,
and G. L. Dohm, “Insulin receptor phosphorylation, insulin
receptor substrate-1 phosphorylation, and phosphatidylinos-
itol 3-kinase activity are decreased in intact skeletal muscle
strips from obese subjects,” Journal of Clinical Investigation,
vol. 95, no. 5, pp. 2195–2204, 1995.
[15] J. T. Brozinick, B. R. Roberts, and G. L. Dohm, “Defective
signaling through Akt-2 and -3 but not Akt-1 in insulin-
resistant human skeletal muscle: potential role in insulin
resistance,” Diabetes, vol. 52, no. 4, pp. 935–941, 2003.
[16] F. Ahmad, J. L. Azevedo, R. Cortright, G. L. Dohm, and
B. J. Goldstein, “Alterations in skeletal muscle protein-
tyrosine phosphatase activity and expression in insulin-
resistant human obesity and diabetes,” Journal of Clinical
Investigation, vol. 100, no. 2, pp. 449–458, 1997.
[17] J. F. Caro, M. K. Sinha, and S. M. Raju, “Insulin receptor
kinase in human skeletal muscle from obese subjects with and
without noninsulin dependent diabetes,” Journal of Clinical
Investigation, vol. 79, no. 5, pp. 1330–1337, 1987.
[18] Q. Zhou, P. L. Dolan, and G. L. Dohm, “Dephosphorylation
increases insulin-stimulated receptor kinase activity in skeletal
muscle of obese Zucker rats,” Molecular and Cellular Biochem-
istry, vol. 194, no. 1-2, pp. 209–216, 1999.
[19] S. I. Itani, Q. Zhou, W. J. Pories, K. G. MacDonald, and G.
L. Dohm, “Involvement of protein kinase C in human skeletal
muscle insulin resistance and obesity,” Diabetes, vol. 49, no. 8,
pp. 1353–1358, 2000.
[20] B. T. Bikman, D. Zheng, W. J. Pories et al., “Mechanism
for improved insulin sensitivity after gastric bypass surgery,”
Journal of Clinical Endocrinology and Metabolism, vol. 93, no.
12, pp. 4656–4663, 2008.
[21] R. N. Cortright, J. L. Azevedo, Q. Zhou et al., “Protein kinase C
modulates insulin action in human skeletal muscle,” American
Journal of Physiology, vol. 278, no. 3, pp. E553–E562, 2000.
[22] G. R. Dagenais, R. G. Tancredi, and K. L. Zierler, “Free fatty
acid oxidation by forearm muscle at rest, and evidence for an
intramuscular lipid pool in the human forearm,” Journal of
Clinical Investigation, vol. 58, no. 2, pp. 421–431, 1976.
[23] F. Zurlo, S. Lillioja, A. E. D. Puente et al., “Low ratio of fat to
carbohydrate oxidation as predictor of weight gain: study of
24-h RQ,” American Journal of Physiology, vol. 259, no. 5, pp.
E650–E657, 1990.
10 Journal of Obesity
[24] F. Zurlo, P. M. Nemeth, R. M. Choksi, S. Sesodia, and
E. Ravussin, “Whole-body energy metabolism and skeletal
muscle biochemical characteristics,” Metabolism, vol. 43, no.
4, pp. 481–486, 1994.
[25] M. W. Hulver, J. R. Berggren, R. N. Cortright et al., “Skeletal
muscle lipid metabolism with obesity,” American Journal of
Physiology, vol. 284, no. 4, pp. E741–E747, 2003.
[26] J. Y. Kim, R. C. Hickner, R. L. Cortright, G. L. Dohm, and J. A.
Houmard, “Lipid oxidation is reduced in obese human skeletal
muscle,” American Journal of Physiology, vol. 279, no. 5, pp.
E1039–E1044, 2000.
[27] J. R. Berggren, K. E. Boyle, W. H. Chapman, and J. A.
Houmard, “Skeletal muscle lipid oxidation and obesity:
influence of weight loss and exercise,” American Journal of
Physiology, vol. 294, no. 4, pp. E726–E732, 2008.
[28] D. S. Hittel, Y. Hathout, E. P. Huﬀman, and J. A. Houmard,
“Proteome analysis of skeletal muscle from obese and mor-
bidly obese women,” Diabetes, vol. 54, no. 5, pp. 1283–1288,
2005.
[29] A. Bonen, M. L. Parolin, G. R. Steinberg et al., “Triacylglycerol
accumulation in human obesity and type 2 diabetes is
associated with increased rates of skeletal muscle fatty acid
transport increased sarcolemmal FAT/CD36,” FASEB Journal,
vol. 18, no. 10, pp. 1144–1146, 2004.
[30] M. W. Hulver, J. R. Berggren, M. J. Carper et al., “Elevated
stearoyl-CoA desaturase-1 expression in skeletal muscle con-
tributes to abnormal fatty acid partitioning in obese humans,”
Cell Metabolism, vol. 2, no. 4, pp. 251–261, 2005.
[31] G. I. Shulman, “Cellular mechanisms of insulin resistance,”
Journal of Clinical Investigation, vol. 106, no. 2, pp. 171–176,
2000.
[32] B. H. Goodpaster, J. He, S. Watkins, and D. E. Kelley, “Skeletal
muscle lipid content and insulin resistance: evidence for a
paradox in endurance-trained athletes,” Journal of Clinical
Endocrinology and Metabolism, vol. 86, no. 12, pp. 5755–5761,
2001.
[33] B. H. Goodpaster, R. Theriault, S. C. Watkins, and D. E.
Kelley, “Intramuscular lipid content is increased in obesity and
decreased by weight loss,” Metabolism, vol. 49, no. 4, pp. 467–
472, 2000.
[34] M. S. Hickey, J. O. Carey, J. L. Azevedo et al., “Skeletal muscle
fiber composition is related to adiposity and in vitro glucose
transport rate in humans,” American Journal of Physiology, vol.
268, no. 3, pp. E453–E457, 1995.
[35] C. J. Tanner, H. A. Barakat, G. Lynis Dohm et al., “Muscle
fiber type is associated with obesity and weight loss,” American
Journal of Physiology, vol. 282, no. 6, pp. E1191–E1196, 2002.
[36] R. E. Gray, C. J. Tanner, W. J. Pories, K. G. MacDonald, and J.
A. Houmard, “Eﬀect of weight loss on muscle lipid content in
morbidly obese subjects,” American Journal of Physiology, vol.
284, no. 4, pp. E726–E732, 2003.
[37] J. A. Houmard, C. J. Tanner, C. Yu et al., “Eﬀect of weight loss
on insulin sensitivity and intramuscular long-chain fatty acyl-
CoAs in morbidly obese subjects,” Diabetes, vol. 51, no. 10, pp.
2959–2963, 2002.
[38] R. R. Henry, T. P. Ciaraldi, L. Abrams-Carter, S. Mudaliar,
K. S. Park, and S. E. Nikoulina, “Glycogen synthase activity
is reduced in cultured skeletal muscle cells of non-insulin-
dependent diabetes mellitus subjects: biochemical and molec-
ular mechanisms,” Journal of Clinical Investigation, vol. 98, no.
5, pp. 1231–1236, 1996.
[39] J. R. Berggren, C. J. Tanner, and J. A. Houmard, “Primary cell
cultures in the study of human muscle metabolism,” Exercise
and Sport Sciences Reviews, vol. 35, no. 2, pp. 56–61, 2007.
[40] D. M. Muoio, J. M. Way, C. J. Tanner et al., “Peroxisome
proliferator-activated receptor-α regulates fatty acid utiliza-
tion in primary human skeletal muscle cells,” Diabetes, vol. 51,
no. 4, pp. 901–909, 2002.
[41] M. Gaster, “Insulin resistance and the mitochondrial link.
Lessons from cultured human myotubes,” Biochimica et
Biophysica Acta - Molecular Basis of Disease, vol. 1772, no. 7,
pp. 755–765, 2007.
[42] M. Gaster, A. C. Rustan, V. Aas, and H. Beck-Nielsen,
“Reduced lipid oxidation in skeletal muscle from type 2
diabetic subjects may be of genetic origin: evidence from
cultured myotubes,” Diabetes, vol. 53, no. 3, pp. 542–548,
2004.
[43] J. A. Bell, “Lipid partitioning, incomplete fatty acid oxidation,
and insulin signal transduction in primary human muscle
cells: eﬀects of severe obesity, fatty acid incubation, and fatty
acid translocase/CD36 overexpression,” American Journal of
Physiology, vol. 95, no. 7, pp. 3400–3410, 2010.
[44] B. T. Bikman, D. Zheng, M. A. Reed, R. C. Hickner, J. A.
Houmard, and G. L. Dohm, “Lipid-induced insulin resistance
is prevented in lean and obesemyotubes by AICAR treatment,”
American Journal of Physiology, vol. 298, no. 6, pp. R1692–
R1699, 2010.
[45] L. A. Consitt, J. A. Bell, T. R. Koves et al., “Peroxisome
proliferator-activated receptor-γ coactivator-1α overexpres-
sion increases lipid oxidation in myocytes from extremely
obese individuals,” Diabetes, vol. 59, no. 6, pp. 1407–1415,
2010.
[46] P. Cohen, M. Miyazaki, N. D. Socci et al., “Role for stearoyl-
CoA desaturase-1 in leptin-mediated weight loss,” Science, vol.
297, no. 5579, pp. 240–243, 2002.
[47] D. S. Hittel, J. R. Berggren, J. Shearer, K. Boyle, and J. A.
Houmard, “Increased secretion and expression of myostatin
in skeletal muscle from extremely obese women,” Diabetes, vol.
58, no. 1, pp. 30–38, 2009.
[48] K. E. Boyle, J. P. Canham, L. A. Consitt et al., “A high-fat diet
elicits diﬀerential responses in genes coordinating oxidative
metabolism in skeletal muscle of lean and obese individuals,”
Journal of Clinical Endocrinology and Metabolism, vol. 96, no.
3, pp. 775–781, 2011.
[49] A. Astrup, B. Buemann, N. J. Christensen, and S. Toubro,
“Failure to increase lipid oxidation in response to increasing
dietary fat content in formerly obese women,” American
Journal of Physiology, vol. 266, no. 4, pp. E592–E599, 1994.
[50] P. Schrauwen, W. D. Van Marken Lichtenbelt, W. H. M. Saris,
and K. R. Westerterp, “Changes in fat oxidation in response to
a high-fat diet,” American Journal of Clinical Nutrition, vol. 66,
no. 2, pp. 276–282, 1997.
[51] N. R. Guesbeck, M. S. Hickey, K. G. MacDonald et al.,
“Substrate utilization during exercise in formerly morbidly
obese women,” Journal of Applied Physiology, vol. 90, no. 3, pp.
1007–1012, 2001.
[52] J. E. Friedman, G. L. Dohm, N. Leggett-Frazier et al.,
“Restoration of insulin responsiveness in skeletal muscle of
morbidly obese patients after weight loss: eﬀect on muscle
glucose transport and glucose transporter GLUT4,” Journal of
Clinical Investigation, vol. 89, no. 2, pp. 701–705, 1992.
[53] W. J. Pories, K. G. MacDonald Jr., E. J. Morgan et al., “Surgical
treatment of obesity and its eﬀect on diabetes: 10-y follow-up,”
American Journal of Clinical Nutrition, vol. 55, no. 2, pp. 582S–
585S, 1992.
Journal of Obesity 11
[54] C. Pender et al., “Muscle insulin receptor concentrations in
obese patients post bariatric surgery: relationship to hyper-
insulinemia,” International Journal of Obesity and Related
Metabolic Disorders, vol. 28, no. 3, pp. 363–369, 2004.
[55] J. J. Park, J. R. Berggren, M. W. Hulver, J. A. Houmard, and E.
P. Hoﬀman, “GRB14, GPD1, and GDF8 as potential network
collaborators in weight loss-induced improvements in insulin
action in human skeletal muscle,” Physiological Genomics, vol.
27, no. 2, pp. 114–121, 2006.
[56] D. E. Befroy, K. F. Petersen, S. Dufour et al., “Impaired
mitochondrial substrate oxidation in muscle of insulin-
resistant oﬀspring of type 2 diabetic patients,” Diabetes, vol.
56, no. 5, pp. 1376–1381, 2007.
[57] C. R. Bruce, M. J. Anderson, A. L. Carey et al., “Muscle
oxidative capacity is a better predictor of insulin sensitivity
than lipid status,” Journal of Clinical Endocrinology and
Metabolism, vol. 88, no. 11, pp. 5444–5451, 2003.
[58] J. P. Thyfault, R. M. Kraus, R. C. Hickner, A. W. Howell, R. R.
Wolfe, and G. L. Dohm, “Impaired plasma fatty acid oxidation
in extremely obese women,” American Journal of Physiology,
vol. 287, no. 6, pp. E1076–E1081, 2004.
[59] E. De Filippis, G. Alvarez, R. Berria et al., “Insulin-resistant
muscle is exercise resistant: evidence for reduced response of
nuclear-encoded mitochondrial genes to exercise,” American
Journal of Physiology, vol. 294, no. 3, pp. E607–E614, 2008.
[60] M. I. Hern´andez-Alvarez, H. Thabit, N. Burns et al., “Subjects
with early-onset type 2 diabetes show defective activation of
the skeletal muscle PGC-1α/mitofusin-2 regulatory pathway
in response to physical activity,” Diabetes Care, vol. 33, no. 3,
pp. 645–651, 2010.
[61] M. S. Hickey, K. E. Gavingan,M. R.McCammon et al., “Eﬀects
of 7 days of exercise training on insulin action in morbidly
obese men,” Clinical Exercise Physiology, vol. 1, pp. 24–28,
1999.
